By
Dan Ahrens, Portfolio Manager of AdvisorShares's Pure US Cannabis ETF (MSOS) and Pure Cannabis ETF (YOLO), joins Nicole Petallides of the Schwab Network to discuss the Trump's Executive Order to reschedule cannabis, including:
- the monumental, albeit volatile, shift in U.S. cannabis regulations
- the potential for significant upside for U.S. cannabis stocks,
- the broader implications for banking and major exchange listings for cannabis companies.
Watch Dan on Schwab Network — by clicking this link you will be leaving our website and accessing a third party website.
|
— For Institutional Investor Use Only. Not for Public Distribution —
|
|
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus and summary prospectus, a copy of which may be obtained by visiting the Fund’s website at www.AdvisorShares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor. MSOS | YOLO: The Fund(s) is subject to a number of risks that may affect the value of its shares. This section provides additional information about the Fund’s principal risks. The degree to which a risk applies to the Fund(s) varies according to its investment allocation. Each investor should review the complete description of the principal risks before investing in the Fund(s). As with investing in other securities whose prices increase and decrease in market value, you may lose money by investing in the Fund(s). Cannabis-Related Company Risk: Cannabis-related companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may (i) significantly affect a cannabis-related company’s ability to secure financing, (ii) impact the market for marijuana industry sales and services, and (iii) set limitations on marijuana use, production, transportation, and storage. Cannabis-related companies may also be required to secure permits and authorizations from government agencies to cultivate or research marijuana. In addition, cannabis-related companies are subject to the risks associated with the greater agricultural industry, including changes to or trends that affect commodity prices, labor costs, weather conditions, and laws and regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use a enforcement of intellectual property rights and patents, technological change and obsolescence, product liability lawsuits, and the risk that research and development may not necessarily lead to commercially successful products. |
